Needham Maintains Buy on Cellebrite DI, Raises Price Target to $10
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Mike Cikos maintains a Buy rating on Cellebrite DI (NASDAQ:CLBT) and raises the price target from $7 to $10.
August 09, 2023 | 8:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Mike Cikos maintains a Buy rating on Cellebrite DI and raises the price target from $7 to $10. This could potentially lead to an increase in the stock's price.
The raised price target by Needham analyst indicates a positive outlook for Cellebrite DI. This could potentially attract more investors, leading to an increase in demand for the stock and subsequently, an increase in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100